News
Events
China Israel Value Capital (CIVC) and Shenzhen Capital Group Co., (SCGC) invested Celgen Biopharmaceutical co, Ltd

China Israel Value Capital (CIVC) and Shenzhen Capital Group Co., (SCGC) invested in Shanghai Celgen Biopharmaceutical co, Ltd ("Celgen"), a leading bio-similar biopharmaceuticals drugs developer and manufacture in China.

 

For the press release please click here.